Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Sentana-Lledo

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
JCO Oncology Practice|March 2, 2026
Subcutaneous Immunotherapy: It Is Time for Real-World DataDaniel Sentana-Lledo, Arjun Gupta
Therapeutic Advances in Medical Oncology|December 12, 2024
Time's up: the urgency to investigate time toxicity in patients with genitourinary malignanciesDaniel Sentana-Lledo, Alicia K Morgans
Urology|March 23, 2023
EDITORIAL COMMENTDaniel Sentana-Lledo, David J Einstein
Current Oncology Reports|February 20, 2024
Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate CancerDaniel Sentana-Lledo, Alicia K Morgans
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy-Related Vasomotor SymptomsDaniel Sentana-Lledo, Alicia K Morgans
Journal of the National Comprehensive Cancer Network : JNCCN|December 20, 2024
Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation TherapyDaniel Sentana-Lledo, Anurag Saraf, Alicia K Morgans
Clinical Genitourinary Cancer|April 7, 2026
Advances in Androgen Deprivation Therapy-Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate CancerAlicia K Morgans, Daniel Sentana-Lledo, Mark Wildgust, et al.
The Prostate|March 7, 2022
Immune mechanisms behind prostate cancer in men of African ancestry: A reviewDaniel Sentana-Lledo, Oliver Sartor, Steven P Balk, et al.
Urologic Oncology|February 8, 2023
Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer PatientsDaniel Sentana-Lledo, Laura E Dodge, Peter Chang, et al.
The Oncologist|May 16, 2025
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of lifeDaniel Sentana-Lledo, Amelia Barnett, David J Einstein, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
JCO Oncology Practice|March 2, 2026
Subcutaneous Immunotherapy: It Is Time for Real-World DataDaniel Sentana-Lledo, Arjun Gupta
Therapeutic Advances in Medical Oncology|December 12, 2024
Time's up: the urgency to investigate time toxicity in patients with genitourinary malignanciesDaniel Sentana-Lledo, Alicia K Morgans
Urology|March 23, 2023
EDITORIAL COMMENTDaniel Sentana-Lledo, David J Einstein
Current Oncology Reports|February 20, 2024
Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate CancerDaniel Sentana-Lledo, Alicia K Morgans
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy-Related Vasomotor SymptomsDaniel Sentana-Lledo, Alicia K Morgans
Journal of the National Comprehensive Cancer Network : JNCCN|December 20, 2024
Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation TherapyDaniel Sentana-Lledo, Anurag Saraf, Alicia K Morgans
Clinical Genitourinary Cancer|April 7, 2026
Advances in Androgen Deprivation Therapy-Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate CancerAlicia K Morgans, Daniel Sentana-Lledo, Mark Wildgust, et al.
The Prostate|March 7, 2022
Immune mechanisms behind prostate cancer in men of African ancestry: A reviewDaniel Sentana-Lledo, Oliver Sartor, Steven P Balk, et al.
Urologic Oncology|February 8, 2023
Prevalence and Morbidity of Local Treatment-Related Side Effects in Metastatic Prostate Cancer PatientsDaniel Sentana-Lledo, Laura E Dodge, Peter Chang, et al.
The Oncologist|May 16, 2025
Days spent with healthcare contact by patients with metastatic castrate resistant prostate cancer in the last year of lifeDaniel Sentana-Lledo, Amelia Barnett, David J Einstein, et al.
Pageof 3